Entera Bio Reports Q2 Results, Plans Phase 3 Osteoporosis Trial for Late 2026
ENTX has more than doubled off its 52-week low of $0.91 on light trading volume (0.1× avg).
Summary
Entera Bio announced Q2 2026 financial results and provided key pipeline updates. The company confirmed FDA alignment on a 12-month registrational Phase 3 study for EB613, its oral osteoporosis drug, with initiation planned for late 2026 and topline data expected in the second half of 2028. This follows the June 2026 positive FDA feedback and the recent $275M oversubscribed private placement that extended its cash runway. The company also disclosed ongoing IND-enabling studies for EB612, a hypoparathyroidism candidate, with an IND filing targeted for the first half of 2027. The update reinforces the company's transition from preclinical to late-stage development, backed by a strong balance sheet. The Phase 3 start and IND filing are key near-term catalysts.
At the time of this announcement, ENTX was trading at $2.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $141.5M. The 52-week trading range was $0.91 to $4.20. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.